The negative prognostic value associated with uPAR stromal expression in multiple cancer types, including breast [135], colon [130], and pancreatic cancer [119], clearly emphasizes this concept and underscores the therapeutic potential of targeting the tumor stroma as a promising adjuvant anti-cancer treatment. This evidence concerns the gene PLAUR and familial pancreatic carcinoma.